PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 04:36:45 2024-06-07 am EDT | ||
| 3.49 EUR | -12.75% |
|
| Current month | -41.26% | ||
| 1 month | -63.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 3.49 | -12.75% |
| 24-06-06 | 4 | +2.30% |
| 24-06-05 | 3.91 | -19.21% |
| 24-06-04 | 4.84 | -9.53% |
| 24-06-03 | 5.35 | -21.44% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 04:36 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8GF4 |
| ISIN | DE000VM8GF47 |
| Date issued | 2024-01-12 |
| Strike | 522.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.43 € |
|---|---|
| Lowest since issue | 3.49 € |
| Spread | 0.18 € |
| Spread % | 4.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
- Stock Market
- Certificates
- Certificat
